Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10816.145 | 1.0281 | 1.0727 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10816.145 | 1.0895 | 1.2333 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10816.145 | 0.9533 | 0.8805 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10816.145 | 1.0547 | 1.1419 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10816.145 | 1.1764 | 1.4653 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10816.145 | 1.1142 | 1.2988 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10816.145 | 1.0625 | 1.1624 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10816.145 | 1.0469 | 1.1215 | 0.7766 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 12319.17 | 1.0594 | 1.2623 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 12319.17 | 0.9877 | 0.9479 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 12319.17 | 1.0814 | 1.3639 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 12319.17 | 0.9221 | 0.6822 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 12319.17 | 0.8291 | 0.3404 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 12319.17 | 0.9630 | 0.8451 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 12319.17 | 1.0408 | 1.1783 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 12319.17 | 1.0382 | 1.1669 | 0.4684 | |
| LY2 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 12319.17 | 0.9843 | 0.9335 | 0.4684 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 0.000512 | uM | 12580.17 | 1.0003 | 1.0003 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 0.00256 | uM | 12580.17 | 1.0169 | 1.0169 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 0.0128 | uM | 12580.17 | 1.0367 | 1.0364 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 0.064 | uM | 12580.17 | 1.0345 | 1.0342 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 0.32 | uM | 12580.17 | 1.0605 | 1.0597 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 1.6 | uM | 12580.17 | 1.0724 | 1.0712 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 8 | uM | 12580.17 | 1.0855 | 1.0837 | 1.9993 | |
| MB 157 | Unknown | Unknown | Nilotinib | ABL | nRTK | 40 | uM | 12580.17 | 1.0390 | 1.0386 | 1.9993 |